ClinicalTrials.gg
CompletedNCT01356849RADARUpdated Aug 28, 2013

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

A Phase 2 interventional study of Atrasentan and Placebo in Chronic Kidney Disease and Diabetic Nephropathy, sponsored by AbbVie (prior sponsor, Abbott). Completed at 72 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-28.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Renal Insufficiency, Chronic by AbbVie — none open to participants now, none under way, none of them phase 3. Renal Insufficiency, Chronic · AbbVie.

Enrollment
2nd of 12
149 · median 62
Started
2011
with 6 others
Phase 2
4 of 19
none open now
Registered
11th of 19
by date

Among the 19 studies in Renal Insufficiency, Chronic by AbbVie, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 7 that started in 2011, is one of 4 in phase 2, and was the 11th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 19 studies in Renal Insufficiency, Chronic by AbbVie is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Renal Insufficiency, Chronic by AbbVie as a file.
02

Study summary

Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared to placebo in reducing residual albuminuria in Type 2 diabetic patients with nephropathy who are treated with the maximum tolerated labeled dose of a Renin Angiotensin System (RAS) inhibitor. If the patient is already receiving a maximum tolerated labeled daily dose of RAS inhibitor and a diuretic, he/she will complete 4 weeks of the Run-in Period on a dose that has not been adjusted. If the patient is currently not receiving a maximum labeled daily dose of a RAS inhibitor then the dose will be titrated up to the maximum tolerated labeled dose over the course of 4 to 8 weeks during the Run-in Period. It is expected that subjects not receiving a diuretic will have a diuretic added or titrated during this period to maximize RAS inhibition. Following titration to the maximum tolerated labeled dose, the patient will complete an additional 4 weeks of Run-In Period on an unchanged doses of RAS inhibitor and diuretics, unless medically contraindicated. The randomization will be stratified based on country where subjects are enrolled into the study, and the Week -1 Urinary Albumin to Creatinine Ratio (UACR) levels (\< or = 1000 mg/g [113 mg/mmol], or > 1000 mg/g [113 mg/mmol]). Within each stratum, subjects will be randomly assigned in a 1:2:2 ratio to one of the following blinded treatment groups: Group A - Placebo once daily (QD) Group B - low dose atrasentan QD Group C - high dose atrasentan QD After the 12 weeks of study drug treatment, subjects will be followed up to 30 days.

03

Conditions studied

  • Chronic Kidney Disease
  • Diabetic Nephropathy

Keywords

  • Endothelin Receptor Antagonists
  • Proteinuria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is > or = 18 years old.
  • Patient has Type 2 diabetes and has been treated with at least one anti hyperglycemic medication within the 12 months prior to the Screening Period.
  • Patient is currently receiving an angiotensin converting enzyme inhibitor (ACEi) or Angiotensin II receptor blocker (ARB) (Renin Angiotensin System (RAS) inhibitor).
  • For entry in the Run-in Period the patient must satisfy the following criteria based on the Screening laboratory values:

    • Estimated (eGFR) ≥ 30 and ≤ 75 mL/min/1.73m2 by Epidemiology Collaboration (EPI) formula
    • Urinary Albumin to Creatinine Ratio (UACR) > or = 300 and \< or = 3500 mg/g as determined by the geometric mean of the two morning void urine specimens obtained at the Screening visit (UACR > or = 34 mg/mmol and \< or = 396 mg/mmol)
    • Serum albumin > or = 3.0 g/dL (30 g/L) - B-type Natriuretic Peptide (BNP) \< or = 200 pg/mL (57.8 pmol/L) * Negative serum pregnancy test for female patients
    • Systolic Blood Pressure (SBP) > or = 110 mmHg and \< or = 180 mmHg
    • Glucosylated (HbA1c) \< or = 12%
  • For entry in the Treatment Period the patient must satisfy the following criteria based on the last visit of the Run-in Period laboratory values:

    • Renin Angiotensin System (RAS) inhibitor at maximum tolerated labeled dose for the previous 4 weeks with no adjustments of dose
    • Diuretic at any dose unless medically (with the exception of loop diuretics > or = 120 mg QD of furosemide or > or = 3.0 mg QD of bumetanide or > or = 150 mg QD of ethacrynic acid or > or = 60 mg QD of torasemide)
    • Urinary Albumin to Creatinine Ratio (UACR) > or = 200 and \< or = 3500 mg/g as determined by the median of the three morning void urine specimens obtained prior to the Week -1 visit (UACR > or = 23 mg/mmol and \< or = 396 mg/mmol)
    • Systolic blood pressure (SBP) > or = 110 mmHg and \< or = 160 mmHg
    • Serum Potassium \< or = 5.5 mEq/L (5.5 mmol/L)
    • Negative serum pregnancy test for female patients

Exclusion criteria

Exclusion Criteria:

  • Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to Screening.
  • Patient is receiving loop diuretics > or = 120 mg QD of furosemide or > or = 3.0 mg QD of bumetanide or > or = 150 mg QD of ethacrynic acid or > or = 60 mg QD of torasemide.
  • Patient has a history of pulmonary edema.
  • Patient has a history of pulmonary hypertension, or any lung diseases requiring oxygen therapy (i.e., , emphysema, pulmonary fibrosis).
  • Patient has a history of orthostatic hypotension within the past 6 months as defined by the presence of a supine-to-standing blood pressure decrease > or = 20 mmHg systolic or > or = 10 mmHg diastolic within 3 minutes of standing.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Placebo comparator
    Group A - Placebo QD

    Drug: Placebo

  • Active comparator
    Group B - Low dose Atrasentan QD

    Drug: Atrasentan

  • Active comparator
    Group C - High dose Atrasentan QD

    Drug: Atrasentan

Interventions

  • Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.

    Also known as: ABT-627

  • DrugPlacebo

    Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.

06

What researchers measure

Primary outcomes

  1. Change from baseline to Week 12 in Urinary Albumin to Creatinine Ratio (UACR)

    Time frame: Every two weeks for 12 weeks

Secondary outcomes

  1. Differences in change from baseline to each post baseline measure for estimated glomerular filtration rate (eGFR)

    Time frame: Every two weeks for 12 weeks

  2. Differences in change from baseline to each post baseline measure for EQ-5D Index Score

    Time frame: Once a month for 3 months

  3. Differences in change from baseline to each post baseline measure for each of the Kidney Disease Quality of Life (KDQOL) Kidney Disease Targeted Scales

    Time frame: Once a month for 3 months

07

Study locations

72 sites
  • Site Reference ID/Investigator# 46345
    Pell City, Alabama 35128, United States
  • Site Reference ID/Investigator# 46035
    Tempe, Arizona 85284, United States
  • Site Reference ID/Investigator# 46016
    Azusa, California 91702, United States
  • Site Reference ID/Investigator# 45992
    Chula Vista, California 91910, United States
  • Site Reference ID/Investigator# 46000
    La Mesa, California 91942, United States
  • Site Reference ID/Investigator# 46038
    Lincoln, California 95648, United States
  • Site Reference ID/Investigator# 45994
    Long Beach, California 90806, United States
  • Site Reference ID/Investigator# 45998
    Los Angeles, California 90022, United States
  • Site Reference ID/Investigator# 47584
    Los Gatos, California 95032, United States
  • Site Reference ID/Investigator# 64465
    National City, California 91950, United States
  • Site Reference ID/Investigator# 65862
    Orange, California 92868, United States
  • Site Reference ID/Investigator# 46019
    Riverside, California 92505, United States
  • Site Reference ID/Investigator# 46110
    Salinas, California 93901, United States
  • Site Reference ID/Investigator# 46017
    Yuba City, California 95991, United States
  • Site Reference ID/Investigator# 46662
    Westminster, Colorado 80031, United States
  • Site Reference ID/Investigator# 46033
    Coral Gables, Florida 33134, United States
  • Site Reference ID/Investigator# 45989
    Hialeah, Florida 33012, United States
  • Site Reference ID/Investigator# 46667
    Lauderdale Lakes, Florida 33313, United States
  • Site Reference ID/Investigator# 46123
    Miami, Florida 33135, United States
  • Site Reference ID/Investigator# 46115
    Ocala, Florida 34471, United States
  • Site Reference ID/Investigator# 46664
    Pembroke Pines, Florida 33027, United States
  • Site Reference ID/Investigator# 46031
    Pembroke Pines, Florida 33028, United States
  • Site Reference ID/Investigator# 46040
    Pembroke Pines, Florida 33028, United States
  • Site Reference ID/Investigator# 46122
    Port Charlotte, Florida 33952, United States
  • Site Reference ID/Investigator# 46015
    West Palm Beach, Florida 33401, United States
  • Site Reference ID/Investigator# 50482
    Jonesboro, Georgia 30236, United States
  • Site Reference ID/Investigator# 46034
    Meridian, Idaho 83642, United States
  • Site Reference ID/Investigator# 46666
    Chicago, Illinois 60616, United States
  • Site Reference ID/Investigator# 45996
    Evergreen Park, Illinois 60805, United States
  • Site Reference ID/Investigator# 46002
    Gurnee, Illinois 60031, United States
  • Site Reference ID/Investigator# 46111
    Shreveport, Louisiana 71101, United States
  • Site Reference ID/Investigator# 46030
    Oxon Hill, Maryland 20745, United States
  • Site Reference ID/Investigator# 45991
    Rockville, Maryland 20852, United States
  • Site Reference ID/Investigator# 46025
    Novi, Michigan 48374, United States
  • Site Reference ID/Investigator# 46023
    Brooklyn Center, Minnesota 55430, United States
  • Site Reference ID/Investigator# 46062
    Farmington, Missouri 63640, United States
  • Site Reference ID/Investigator# 48942
    Omaha, Nebraska 68131-3403, United States
  • Site Reference ID/Investigator# 46349
    Omaha, Nebraska 68131, United States
  • Site Reference ID/Investigator# 46116
    Las Vegas, Nevada 89106, United States
  • Site Reference ID/Investigator# 50483
    Albany, New York 12206, United States
  • Site Reference ID/Investigator# 68328
    New Hyde Park, New York 11042, United States
  • Site Reference ID/Investigator# 65863
    Asheville, North Carolina 28801, United States
  • Site Reference ID/Investigator# 50529
    Greensboro, North Carolina 27408, United States
  • Site Reference ID/Investigator# 46129
    Greenville, North Carolina 27834, United States
  • Site Reference ID/Investigator# 46022
    Morehead City, North Carolina 28557, United States
  • Site Reference ID/Investigator# 46224
    Doylestown, Pennsylvania 18901, United States
  • Site Reference ID/Investigator# 46028
    Orangeburg, South Carolina 29118, United States
  • Site Reference ID/Investigator# 46702
    Orangeburg, South Carolina 29118, United States
  • Site Reference ID/Investigator# 46024
    Greenville, Texas 75402, United States
  • Site Reference ID/Investigator# 46228
    Houston, Texas 77004, United States
  • Site Reference ID/Investigator# 47068
    Houston, Texas 77004, United States
  • Site Reference ID/Investigator# 64464
    Houston, Texas 77054, United States
  • Site Reference ID/Investigator# 64483
    Mission, Texas 78572, United States
  • Site Reference ID/Investigator# 46348
    San Antonio, Texas 78215, United States
  • Site Reference ID/Investigator# 46063
    San Antonio, Texas 78229-4801, United States
  • Site Reference ID/Investigator# 68486
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 46669
    Bennington, Vermont 05201, United States
  • Site Reference ID/Investigator# 46026
    Alexandria, Virginia 22304, United States
  • Site Reference ID/Investigator# 46027
    Fairfax, Virginia 22030, United States
  • Site Reference ID/Investigator# 67762
    Kitchener, N2H 5Z8, Canada
  • Site Reference ID/Investigator# 50526
    Sarnia, N7T 4X3, Canada
  • Site Reference ID/Investigator# 50525
    Thornhill, L4J 8L7, Canada
  • Site Reference ID/Investigator# 47067
    Caguas, 00725, Puerto Rico
  • Site Reference ID/Investigator# 50522
    Manati, 00674, Puerto Rico
  • Site Reference ID/Investigator# 46352
    Ponce, 00717-1322, Puerto Rico
  • Site Reference ID/Investigator# 46351
    Ponce, 00717-2075, Puerto Rico
  • Site Reference ID/Investigator# 46133
    Ponce, 00717, Puerto Rico
  • Site Reference ID/Investigator# 46131
    Rio Piedras, 00935, Puerto Rico
  • Site Reference ID/Investigator# 46132
    San Juan, 00918, Puerto Rico
  • Site Reference ID/Investigator# 46230
    Santurce, 00909-2244, Puerto Rico
  • Site Reference ID/Investigator# 51566
    Taichung City, 40447, Taiwan
  • Site Reference ID/Investigator# 51567
    Taichung, 40705, Taiwan
08

References and documents

Publications

  • Lin CW, Mostafa NM, L Andress D, J Brennan J, Klein CE, Awni WM. Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy. Clin Ther. 2018 Feb;40(2):242-251. doi: 10.1016/j.clinthera.2017.07.011. Epub 2017 Jul 27. PubMed 28756065 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2011
First posted
May 20, 2011
Start
Apr 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results delay requested
Aug 20, 2013
Last update
Aug 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01356849
Responsible party
Sponsor
First posted
May 20, 2011
Start date
Apr 2011
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Aug 28, 2013

Study contacts

Blai Coll, MD
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion